CSL Ltd
ASX:CSL
CSL Ltd
ASX:CSL
Price:
130
AUD
0.78%
Market Closed
Market Cap:
AU$63.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
CSL Ltd
ASX:CSL
|
AU |
Multiples-Based Value
The
Multiples-Based Value for
CSL Ltd (CSL)
under the Base Case is
271.3
AUD.
Compared with the current market price of 130 AUD, the stock appears
Undervalued by 52%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CSL
Multiples-Based Value
271.3
AUD
Undervaluation 52%
Multiples Across Competitors
CSL Competitors Multiples
CSL Ltd Competitors
CSL Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 2.8 | 30.7 | 10.5 | 13.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 5.7 | 83.9 | 14 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 5 | 24.1 | 14 | 14 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.5 | 19 | 11.9 | 14.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9.1 | 27.6 | 20.7 | 21.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 5.5 | 17.6 | 13.1 | 14.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 11.6 | 37.3 | 40.2 | 41.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD | 10.9 | 128.9 | 71.8 | 79.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
